Magnetic resonance imaging of epilepsy in multiple sclerosis: A case control study. Implications for treatment trials with 4-aminopyridine

Multiple Sclerosis

Volumn 1, Issue 4, 1996, Pages 213-217

  Truyen, L ^a   Barkhof, F ^a   Frequin, S T F M ^b   Polman, C H ^a   Tobi, H ^c   Hommes, O R ^b   Valk, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cortical lesions; Epilepsy; Magnetic resonance imaging; Multiple sclerosis; Patient management

Indexed keywords

4 AMINOPYRIDINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; EPILEPSY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; RISK; ROC CURVE;

4-AMINOPYRIDINE; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CLINICAL TRIALS; EPILEPSY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ODDS RATIO; PREVALENCE; ROC CURVE;

EID: 0030072688     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100405     Document Type: Article

References (11)

1. Ghezzi A et al. (1990) Epilepsy in multiple sclerosis. Eur Neurol 30: 218-223.
2. Matthews WB. (1991) Symptoms and signs. In: Matthews WB, Compston A, Allen IV, Martyn CN (eds.) McAlpine's multiple sclerosis. 2nd ed. Churchill-Livingstone, Edinburgh. pp 61-63.
3. Thompson AJ et al. (1994) Seizures due to multiple sclerosis: seven patients with MR imaging correlations. J Neurol Neurosurg Psychiatry 56: 1317-1320.
4. Barkhof F. (1992) Cortical MS lesions: improved detection with gadolinium. In F Barkhof, Gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Thesis, Free University Press, Amsterdam, pp 46-51.
5. Brownell B, Hughes JT. (1962) The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 25: 312-320.
6. Polman CH, Bertelsmann FW, Van Loenen AC, Koetsier JC. (1994) 4-Aminopyridine in the treatment of patients with multiple sclerosis: long term efficacy and safety. Arch Neurol 51: 292-296.
7. Bever CT et al. (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo controlled, double-blind, concentration controlled, crossover trial. Neurology 44: 1054-1059.
8. Poser CM. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
9. Connel FA, Koepsell TD. (1985) Measures of gain in certainty from a diagnostic test. Am J Epidemiol 121: 744-753.
10. Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
11. Murray NMF, Newsom-Davis J. (1981) Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31: 265-271.